Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis
- PMID: 3326741
- DOI: 10.1007/BF02013055
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis
Abstract
The clinical efficacy of the conventional aminoglycoside plus beta-lactam treatment was compared to that of monotherapy with oral quinolones in 26 adult cystic fibrosis patients in an open prospective clinical trial in which six two-week courses of antipseudomonas treatment were administered with an interval of approximately three months between treatments. In each patient two courses of conventional treatment were followed by two courses of quinolone treatment and then by another two courses of conventional treatment. The observed improvements in pulmonary function were somewhat higher when the patients received conventional treatments, and in the most seriously affected patients conventional treatment was significantly better than quinolone treatment. On the basis of these findings it is suggested that quinolone monotherapy cannot replace conventional antipseudomonal chemotherapy in patients with severe pulmonary involvement.
Similar articles
-
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.J Antimicrob Chemother. 1987 Oct;20(4):585-94. doi: 10.1093/jac/20.4.585. J Antimicrob Chemother. 1987. PMID: 3479420 Clinical Trial.
-
Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):316-24. doi: 10.1007/BF01967005. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1907546 Review.
-
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].Infection. 1986;14 Suppl 1:S82-6. doi: 10.1007/BF01645207. Infection. 1986. PMID: 2937740 Clinical Trial. German.
-
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.Pediatr Infect Dis J. 1997 Jan;16(1):97-105; discussion 123-6. doi: 10.1097/00006454-199701000-00031. Pediatr Infect Dis J. 1997. PMID: 9002118 Clinical Trial.
-
Quinolones in the treatment of bronchopulmonary infections.Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S212-7. doi: 10.1093/clinids/10.supplement_1.s212. Rev Infect Dis. 1988. PMID: 3279495 Review.
Cited by
-
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.Pharmacoeconomics. 1993 May;3(5):398-421. doi: 10.2165/00019053-199303050-00007. Pharmacoeconomics. 1993. PMID: 10146890 Review.
-
Fluoroquinolone antimicrobial agents.Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378. Clin Microbiol Rev. 1989. PMID: 2680058 Free PMC article. Review.
-
Use of quinolones in pediatrics.Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):355-60. doi: 10.1007/BF01967011. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1864297 Review.
-
Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.Paediatr Drugs. 2000 Nov-Dec;2(6):451-63. doi: 10.2165/00128072-200002060-00004. Paediatr Drugs. 2000. PMID: 11127845 Review.
-
The quinolones. An overview of their pharmacology.Clin Pharmacokinet. 1992;22 Suppl 1:1-11. doi: 10.2165/00003088-199200221-00003. Clin Pharmacokinet. 1992. PMID: 1319865 Review.